BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9516917)

  • 1. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
    Eder JP; Supko JG; Lynch T; Bryant M; Vosburgh E; Shulman LN; Xu G; Kufe DW
    Clin Cancer Res; 1998 Feb; 4(2):317-24. PubMed ID: 9516917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
    Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
    Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
    Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
    Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
    Eckhardt SG; Baker SD; Eckardt JR; Burke TG; Warner DL; Kuhn JG; Rodriguez G; Fields S; Thurman A; Smith L; Rothenberg ML; White L; Wissel P; Kunka R; DePee S; Littlefield D; Burris HA; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Mar; 4(3):595-604. PubMed ID: 9533526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.
    Leguizamo J; Quinn M; Takimoto CH; Liang MD; Ismail AS; Pang J; Dahut W; Grem JL
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):333-8. PubMed ID: 12819941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.
    Siu LL; Oza AM; Eisenhauer EA; Firby PS; Thiessen JJ; Michael M; Wainman N; Manzo J; Feld R; Goldberg RA; Moore MJ
    J Clin Oncol; 1998 Mar; 16(3):1122-30. PubMed ID: 9508199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
    Zamboni WC; Goel S; Iqbal T; Parise RA; Strychor S; Repinski TV; Egorin MJ; Mani S
    Cancer Chemother Pharmacol; 2006 May; 57(5):631-9. PubMed ID: 16205924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
    Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S; Sorich J; O'Leary J
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
    Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
    Zamboni WC; Jung LL; Egorin MJ; Potter DM; Friedland DM; Belani CP; Agarwala SS; Wong MM; Fakih M; Trump DL; Jin R; Strychor S; Vozniak M; Troetschel M; Ramanathan RK
    Clin Cancer Res; 2004 Aug; 10(15):5058-64. PubMed ID: 15297407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients.
    Thomas RR; Dahut W; Harold N; Grem JL; Monahan BP; Liang M; Band RA; Cottrell J; Llorens V; Smith JA; Corse W; Arbuck SG; Wright J; Chen AP; Shapiro JD; Hamilton JM; Allegra CJ; Takimoto CH
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):215-22. PubMed ID: 11592343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
    Jung LL; Ramanathan RK; Egorin MJ; Jin R; Belani CP; Potter DM; Strychor S; Trump DL; Walko C; Fakih M; Zamboni WC
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):487-96. PubMed ID: 15322760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
    Hochster H; Plimack ER; Runowicz CD; Speyer J; Wallach RC; Sorich J; Mandeli J; Wadler S; Wright J; Muggia FM
    J Clin Oncol; 2004 Jan; 22(1):120-6. PubMed ID: 14701774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
    Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.